| Q50786310 | 42nd annual meeting of the American Society of Clinical Oncology June 2006, Atlanta, GA. |
| Q35134208 | A cyclin-D1 interaction with BAX underlies its oncogenic role and potential as a therapeutic target in mantle cell lymphoma |
| Q81599306 | A high density assay format for the detection of novel cytotoxic agents in large chemical libraries |
| Q33399582 | A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma |
| Q34663617 | A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL). |
| Q40202733 | Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma |
| Q29622918 | Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma |
| Q33394873 | Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma |
| Q36117384 | Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study |
| Q38582650 | Bortezomib in the treatment of mantle cell lymphoma |
| Q47625313 | Clinicopathological Features of Ocular Adnexal Mantle-Cell Lymphoma in an International Multicenter Cohort. |
| Q82458861 | Complete remission of mantle-cell non-Hodgkin lymphoma with a dendritic cell vaccine |
| Q26779612 | Cost-effectiveness analysis of bortezomib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (VR-CAP) in patients with previously untreated mantle cell lymphoma |
| Q36903738 | Current management of mantle cell lymphoma |
| Q37956405 | Current status of targeted therapies for mantle cell lymphoma |
| Q37763618 | Current treatment strategy and new agents in mantle cell lymphoma |
| Q39882401 | Cyclin D1 as a universally expressed mantle cell lymphoma-associated tumor antigen for immunotherapy |
| Q36091283 | Direct and immune-mediated cytotoxicity of interleukin-21 contributes to antitumor effects in mantle cell lymphoma |
| Q92974252 | Effects of the Proteasome Inhibitor Bortezomib in Combination with Chemotherapy for the Treatment of Mantle Cell Lymphoma: A Meta-analysis |
| Q40157194 | Evaluation of novel cell cycle inhibitors in mantle cell lymphoma |
| Q37598141 | Exploring mammalian target of rapamycin (mTOR) inhibition for treatment of mantle cell lymphoma and other hematologic malignancies |
| Q27851412 | Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics |
| Q37728866 | Hematopoietic SCT for mantle cell lymphoma: is it the standard of care? |
| Q35878937 | High-resolution chromatin immunoprecipitation (ChIP) sequencing reveals novel binding targets and prognostic role for SOX11 in mantle cell lymphoma. |
| Q51566016 | Identified hidden genomic changes in mantle cell lymphoma using high-resolution single nucleotide polymorphism genomic array. |
| Q37474352 | Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909. |
| Q33583302 | Indian Council of Medical Research Consensus Document for the Management of Non-Hodgkin's Lymphoma (High Grade). |
| Q37671462 | Long-term outcomes of high dose treatment and autologous stem cell transplantation in follicular and mantle cell lymphomas - a single centre experience |
| Q36301583 | Long-term results of the treatment of patients with mantle cell lymphoma with cladribine (2-CDA) alone (95-80-53) or 2-CDA and rituximab (N0189) in the North Central Cancer Treatment Group. |
| Q35941514 | Low levels of miR-92b/96 induce PRMT5 translation and H3R8/H4R3 methylation in mantle cell lymphoma |
| Q37320512 | Mantle cell lymphoma of the gastrointestinal tract presenting with multiple intussusceptions--case report and review of literature |
| Q38403514 | Mantle cell lymphoma of the oral cavity with multiple foci: a case report and review of the literature |
| Q42080758 | Mantle cell lymphoma salvage regimen: synergy between a reprogrammed oncolytic virus and two chemotherapeutics. |
| Q37622873 | Mantle cell lymphoma: state-of-the-art management and future perspective |
| Q79780494 | Meeting highlights from: 47th Annual Meeting of the American Society of Hematology December 2005, Atlanta, GA |
| Q37152738 | Molecular genetic characterization reveals new subsets of mantle cell lymphoma |
| Q37401338 | Molecular outcome prediction in mantle cell lymphoma |
| Q33961538 | Nanopharmacology in translational hematology and oncology |
| Q41810898 | Non-polypoidal, synchronous mantle-cell lymphoma of small intestine: a rare case |
| Q28087748 | Outcomes of both abbreviated hyper-CVAD induction followed by autologous hematopoietic cell transplantation and conventional chemotherapy for mantle cell lymphoma: a 10-year single-centre experience with literature review |
| Q35037756 | Peripheral blood complete remission after splenic irradiation in mantle-cell lymphoma with 11q22-23 deletion and ATM inactivation |
| Q34498655 | Phase 1b study of otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR™ therapeutic protein, in combination with rituximab and bendamustine in relapsed indolent lymphoma patients |
| Q35932214 | Primary gastric mantle cell lymphoma |
| Q42010612 | Primary gastrointestinal lymphoma |
| Q36668251 | Primary gastrointestinal tract lymphoma: diagnosis and management of common neoplasms |
| Q38354225 | Primary lymphomas in the gastrointestinal tract |
| Q41971312 | Protein profiling of plasma membranes defines aberrant signaling pathways in mantle cell lymphoma. |
| Q35835983 | Relapsed and/or Refractory Mantle Cell Lymphoma: What Role for Temsirolimus? |
| Q46909218 | Rituximab, gemcitabine and oxaliplatin: an effective regimen in patients with refractory and relapsing mantle cell lymphoma |
| Q52609176 | SOX11 augments BCR signaling to drive MCL-like tumor development. |
| Q81752872 | Specific lentiviral shRNA-mediated knockdown of cyclin D1 in mantle cell lymphoma has minimal effects on cell survival and reveals a regulatory circuit with cyclin D2 |
| Q38810148 | Stat3 inhibition augments the immunogenicity of B-cell lymphoma cells, leading to effective antitumor immunity |
| Q54372017 | Stem-like tumor cells confer drug resistant properties to mantle cell lymphoma. |
| Q39886727 | Styryl sulfonyl compounds inhibit translation of cyclin D1 in mantle cell lymphoma cells |
| Q36007656 | Suberoylanilide hydroxamic acid (SAHA; vorinostat) suppresses translation of cyclin D1 in mantle cell lymphoma cells |
| Q36889248 | Targeting Mantle Cell Lymphoma with Anti-SYK Nanoparticles. |
| Q37810084 | Temsirolimus for the treatment of mantle cell lymphoma |
| Q41851673 | The effect of Bortezomib and Rapamycin on Telomerase Activity in Mantle Cell Lymphoma |
| Q37063441 | The epigenetics of mantle cell lymphoma |
| Q44180625 | Treatment with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone combined with cytarabine and methotrexate results in poor mobilization of peripheral blood stem cells in patients with mantle cell lymphoma |
| Q24655119 | Truncation in CCND1 mRNA alters miR-16-1 regulation in mantle cell lymphoma |
| Q36364527 | Update on the molecular biology of mantle cell lymphoma |
| Q79791513 | [Recurrent varicella in a woman with mantle cell lymphoma] |